The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...

Ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) were provided by 23 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a concise ...

After years of controversy, stem cells are on the cusp of cures for conditions like epilepsy and type 1 diabetes.

Vertex Pharmaceuticals Incorporated ... Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics.

Vertex Pharmaceuticals Inc. (NASDAQ ... itself as a dominant player in the CF treatment market, with a strong product lineup that continues to drive revenue growth. The company's focus on ...

Vertex Pharmaceuticals stock declined almost 13 ... Consistent Rise in VRTX’s CF Product Sales Vertex’s cystic franchise (“CF”) sales continue to grow, driven by higher sales of Trikafta ...

The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $416.96, reflecting a -1.72% shift from the previouse trading day's closing. The stock's performance was behind ...

Cantor Fitzgerald analyst Olivia Brayer maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target of $480.00. The company’s shares closed ...

Vertex Pharmaceuticals (VRTX) ended the recent trading session at $468.09, demonstrating a +0.94% swing from the preceding day's closing price. This change outpaced the S&P 500's 0.38% gain on the ...